On May 2, 2025, analyst Jeff Johnson from Baird announced an update regarding DexCom (DXCM, Financial), maintaining an "Outperform" rating while adjusting the stock's price target. The previous price target was set at $115.00 USD.
The new price target for DexCom (DXCM, Financial) is now $105.00 USD, reflecting a decrease of 8.70%. This adjustment in price targets comes amidst ongoing market evaluations. However, the "Outperform" rating remains unchanged, indicating continued confidence in the company's potential performance in the stock market despite the revised outlook.
DexCom (DXCM, Financial), a key player in the medical technology industry, continues to be a subject of close monitoring by investors and analysts alike. The maintained rating of "Outperform" suggests that despite the downward revision, Baird anticipates favorable conditions for DexCom in the foreseeable future.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for DexCom Inc (DXCM, Financial) is $99.44 with a high estimate of $115.00 and a low estimate of $80.00. The average target implies an upside of 41.54% from the current price of $70.26. More detailed estimate data can be found on the DexCom Inc (DXCM) Forecast page.
Based on the consensus recommendation from 27 brokerage firms, DexCom Inc's (DXCM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for DexCom Inc (DXCM, Financial) in one year is $176.41, suggesting a upside of 151.08% from the current price of $70.26. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the DexCom Inc (DXCM) Summary page.
